Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.
Di Giacomo, A
de Rosa, F
Lorigan, Paul C
AffiliationThe Christie NHS Foundation Trust, and University of Manchester, Manchester, UK
MetadataShow full item record
AbstractMost metastatic melanoma patients treated with BRAF inhibitors (BRAFi) ± MEK inhibitors (MEKi) eventually progress on treatment. Along with acquired resistance due to genetic changes, epigenetic mechanisms that could be reversed after BRAFi discontinuation have been described. The purpose of this study was to analyse retrospectively outcomes for patients retreated with BRAF-directed therapy.
CitationRechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. 2018, 91:116-124 Eur J Cancer
JournalEuropean Journal of Cancer